BMY
BRISTOL MYERS SQUIBB CO
NYSE: BMY · Princeton, NJ · Healthcare
$66.82-1.27 (-1.87%)Closed
Market Cap$136.49B
Cash$8.89Bmost recent
Runwayprofitable
P/E (TTM)19.3EPS $3.46
52-Wk Range$41.21 – $68.09
Avg Volume13.3M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$66.82+47.2%
Pipeline
Drug candidates sponsored by BRISTOL MYERS SQUIBB · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs) | HIV-Associated Lipodystrophy Syndrome | Completed | 2007-07past | 1 | |
| Phase 4 | Entecavir | Chronic Hepatitis B | Completed | 2009-01past | 1 | |
| Phase 4 | Apixaban | Acute Coronary Syndromes+7 more | Completed | 2018-11-10past | 7 | |
| Phase 4 | Ozanimod | Colitis, Ulcerative+3 more | Recruiting | 2027-03-31 | 4 | |
| Phase 3 | Stavudine | AIDS Dementia Complex+1 more | Completed | 1999-03past | 1 | |
| Phase 3 | Muraglitazar | Type 2 Diabetes Mellitus | Completed | 2006-08past | 1 | |
| Phase 2 | pexacerfont | Generalized Anxiety Disorder | Completed | 2008-03past | 1 | |
| Phase 3 | Unnamed | Rheumatoid Arthritis (RA) | Completed | 2010-02past | 1 | |
| Phase 2 | Corticosteroids (prednisone or prednisolone) | Systemic Lupus Erythematosus | Terminated | 2010-09past | 1 | |
| Phase 3 | Atazanavir powder | HIV Infections | Completed | 2012-10-04past | 1 | |
| Phase 3 | DCV/ASV/BMS-791325 | Hepatitis C Virus+1 more | Completed | 2015-06-12past | 2 | |
| Phase 3 | dasatinib | Myeloid Leukemia, Chronic, Accelerated Phase+4 more | Completed | 2015-12past | 3 | |
| Phase 3 | BMS-188667 | Lupus Nephritis | Terminated | 2016-11-21past | 1 | |
| Phase 3 | Xanomeline and Trospium Chloride Capsules | Schizophrenia | Completed | 2023-10-03past | 1 | |
| Phase 3 | Nivolumab/rHuPH20 | Melanoma | Completed | 2024-02-08past | 1 | |
| Phase 3 | KarXT | Psychosis Associated With Alzheimer's Disease | Recruiting | 2026-12-09 | 1 | |
| Phase 2 | Iza-bren | Urothelial Cancer | Recruiting | 2029-01-26 | 1 | |
| Phase 3 | BMS-986278 | Pulmonary Fibrosis | Not yet recruiting | 2029-11-22 | 1 | |
| Phase 3 | Nivolumab | Squamous Cell Non-small Cell Lung Cancer+6 more | Recruiting | 2030-07-30 | 6 | |
| Phase 3 | Belatacept | Renal Allograft Recipients | Recruiting | 2032-12-30 | 1 | |
| Phase 2 | BMS-275183 (oral taxane) | Non-small Cell Lung Cancer | Terminated | 2007-03past | 1 | |
| Phase 2 | Paclitaxel | Head and Neck Cancer | Completed | 2008-11-26past | 1 | |
| Phase 2 | Ixabepilone | Breast Cancer | Completed | 2009-12past | 1 | |
| Phase 2 | Atazanavir | HIV | Terminated | 2010-01past | 1 | |
| Phase 2 | BMS-770767 | Diabetes Type 2 | Completed | 2011-01past | 1 | |
| Phase 2 | Placebo | Hepatitis C Virus | Completed | 2012-05past | 1 | |
| Phase 2 | Duloxetine | Depression | Completed | 2013-01past | 1 | |
| Phase 2 | Pegylated Interferon Lambda | Hepatitis C | Completed | 2014-04past | 1 | |
| Phase 2 | BMS-986322 | Psoriasis | Completed | 2024-08-06past | 1 | |
| Phase 2 | Deucravacitinib | Lupus Erythematosus, Discoid+1 more | Active, not recruiting | 2024-08-22past | 1 | |
| Phase 1 | BMS-986249 | Advanced Cancer | Completed | 2024-11-07past | 1 | |
| Phase 2 | Oral Azacitidine | Acute Myeloid Leukemia | Active, not recruiting | 2025-01-27past | 1 | |
| Phase 1 | Relatlimab | Advanced Cancer | Completed | 2025-02-19past | 2 | |
| Phase 2 | Aurexis® | Staphylococcus Aureus Bacteremia | Completed | — | 1 | |
| Phase 1 | BMS-690514 | Cancer | Completed | 2008-07past | 1 | |
| Phase 1 | AR Antagonist (BMS-641988) | Prostate Cancer | Completed | 2009-03past | 1 | |
| Phase 1 | MDX-1106 | Carcinoma, Non-Small-Cell Lung+4 more | Completed | 2009-11past | 1 | |
| Phase 1 | BMS-866949 | Depression | Completed | 2010-03past | 1 | |
| Phase 1 | BMS-820132 | Diabetes Mellitus, Non-Insulin-Dependent | Completed | 2010-10past | 1 | |
| Phase 1 | CT-322 | Glioblastoma Multiforme | Unknown | 2010-10past | 1 | |
| Phase 1 | metoprolol | Atrial Fibrillation | Completed | 2010-11past | 1 | |
| Phase 1 | AntiCD137 | Melanoma | Withdrawn | 2012-07past | 1 | |
| Phase 1 | BMS-833923 | Small Cell Lung Carcinoma | Completed | 2012-09past | 1 | |
| Phase 1 | MDX-1203 | Renal Cell Carcinoma+1 more | Completed | 2012-11past | 1 | |
| Phase 1 | BMS-936558 (MDX-1106) | Metastatic Castration-resistant Prostrate Cancer+3 more | Completed | 2013-02-04past | 1 | |
| Phase 1 | Midazolam | Hepatitis C | Completed | 2013-09past | 1 | |
| Phase 1 | BMS-936559 (Anti-PD-L1) | Stage III or IV Melanoma | Withdrawn | 2013-11past | 1 | |
| Phase 1 | BMS-919373 | Acute Coronary Syndromes | Completed | 2014-05past | 1 | |
| Phase 1 | Abatacept | Rheumatoid Arthritis | Completed | 2014-11past | 1 | |
| Phase 1 | Denenicokin | Neoplasms by Site | Completed | 2014-12past | 1 | |
| Phase 1 | BMS-936559 | Severe Sepsis+1 more | Terminated | 2017-03-15past | 1 | |
| Phase 1 | FS102 | Solid Tumors That Overexpress HER2 (HER2 Positive) | Completed | 2017-06-08past | 1 | |
| Phase 1 | BMS-986165 | Healthy Subjects+5 more | Completed | 2018-10-10past | 4 | |
| Phase 1 | BMS-986166 | Healthy+1 more | Completed | 2022-01-25past | 2 | |
| Phase 1 | [14C]-BMS-986196 | Healthy Male Volunteers | Completed | 2023-10-22past | 1 | |
| Phase 1 | CC-95251 | Leukemia, Myeloid, Acute+1 more | Terminated | 2024-07-30past | 1 | |
| Phase 1 | BMS-986435 | Healthy Participants | Completed | 2025-02-19past | 1 | |
| Phase 1 | BMS-986360 | Advanced Solid Tumors | Completed | 2025-05-12past | 1 | |
| Phase 1 | Golcadomide | Kidney Failure, Chronic | Not yet recruiting | 2026-12-14 | 1 | |
| Phase 1 | BMS-986484 | Advanced Solid Tumors | Active, not recruiting | 2027-10-14 | 1 | |
| Phase 1 | BMS-986500 | Advanced Solid Tumor+2 more | Recruiting | 2028-12-14 | 1 | |
| Phase 1 | vinflunine + ketaconazole | Cancer | Completed | — | 1 | |
| N/A | Unnamed | Non-Valvular Atrial Fibrillation | Completed | 2014-11past | 1 | |
| N/A | Unnamed | Stage III Melanoma | Completed | 2015-11past | 1 | |
| N/A | Unnamed | Juvenile Idiopathic Arthritis | Completed | 2016-09-30past | 1 | |
| N/A | Unnamed | Melanoma | Completed | 2018-02-20past | 1 | |
| N/A | Unnamed | Advanced Cutaneous Melanoma | Completed | 2018-03-30past | 1 | |
| N/A | Orencia | Rheumatoid Arthritis | Withdrawn | 2018-12-31past | 1 | |
| N/A | Unnamed | Melanoma | Completed | 2022-06-02past | 1 | |
| N/A | Unnamed | Non-Small Cell Lung Cancer+1 more | Completed | 2023-02-13past | 1 | |
| N/A | Unnamed | Melanoma | Completed | 2023-04-26past | 1 | |
| N/A | Luspatercept | Myelodysplastic Syndromes | Completed | 2025-03-10past | 1 | |
| N/A | Immunotherapy | Cancer+1 more | Completed | 2025-06-12past | 1 | |
| N/A | Unnamed | Multiple Sclerosis, Relapsing-Remitting | Completed | 2025-07-03past | 1 | |
| N/A | Antifibrotic therapy | Pulmonary Fibrosis+2 more | Not yet recruiting | 2027-05-31 | 1 | |
| N/A | Idecabtagene vicleucel | Multiple Myeloma | Active, not recruiting | 2027-07-31 | 1 | |
| N/A | Unnamed | Unresectable Hepatocellular Carcinoma | Recruiting | 2028-02-29 | 1 | |
| N/A | Unnamed | Multiple Sclerosis | Recruiting | 2032-06-30 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for BMY. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.